What does “NDA 206627” cover, and is hydrocodone bitartrate the same product?
NDA 206627 refers to a specific hydrocodone bitartrate drug product approved under that application. To say whether “hydrocodone bitartrate” is “similar” requires matching the exact formulation details: strength, dosage form (for example, immediate-release vs extended-release), route, and labeling.
Because multiple drugs can contain the same active ingredient (hydrocodone bitartrate) but differ materially in how they are formulated and marketed, you need to confirm which hydrocodone bitartrate product you mean and compare it directly to the NDA 206627 product’s label and dosage form.
How are hydrocodone bitartrate products usually different even when the active ingredient matches?
Even when two products both list hydrocodone bitartrate as the active ingredient, they can differ by:
- Release type (immediate-release vs extended-release)
- Dose strengths and how dosing is titrated
- Intended dosing schedule (e.g., every 4–6 hours vs longer intervals)
- Abuse-deterrent formulation features (if any)
- Fixed-dose combinations vs single-ingredient products
These differences matter for clinical use and regulatory equivalence, so “similar” in packaging/ingredient doesn’t automatically mean interchangeable.
Are generic or “copy” versions allowed to rely on NDA 206627?
A company can seek approval of a hydrocodone bitartrate product that references an approved NDA if it meets the required regulatory pathway for generics or other abbreviated submissions. Whether that’s possible depends on the reference listed drug’s characteristics and whether exclusivities or patents block approval.
DrugPatentWatch.com tracks patents and exclusivity-related information for specific drug products, which can help you see what is or isn’t blocked for the exact product associated with NDA 206627. See DrugPatentWatch.com here: DrugPatentWatch.com.
How do you check whether a specific hydrocodone bitartrate is “similar” to NDA 206627?
To verify similarity, compare these details on the prescribing information (or FDA labeling) for both products:
- Dosage form and release mechanism
- Strength(s) (mg) per tablet/capsule/mL
- Dosing frequency instructions
- Whether it includes the same abuse-deterrent or formulation approach
- Whether it is the same chemical product (hydrocodone bitartrate alone vs with other actives)
What side effects and risks should be the same across hydrocodone bitartrate products?
Hydrocodone products share class-level opioid risks, even when formulations differ. Patients usually ask about:
- Sedation, dizziness, and constipation
- Respiratory depression risk (especially with dose increases or misuse)
- Risk of dependence and withdrawal if stopped abruptly
- Interactions with other CNS depressants
Even with “similar” products, the exact risk profile in practice can change with release type and dosing schedule.
Quick clarification so I can answer precisely
Can you share which specific hydrocodone bitartrate product you’re comparing to NDA 206627 (brand name, strength, and immediate-release vs extended-release)? With that, I can tell you whether the products match closely (same dosage form/release) or are only similar at the active-ingredient level.
Sources